DE69933891T2 - Behandlung von papillomavirus-infektionen - Google Patents

Behandlung von papillomavirus-infektionen Download PDF

Info

Publication number
DE69933891T2
DE69933891T2 DE69933891T DE69933891T DE69933891T2 DE 69933891 T2 DE69933891 T2 DE 69933891T2 DE 69933891 T DE69933891 T DE 69933891T DE 69933891 T DE69933891 T DE 69933891T DE 69933891 T2 DE69933891 T2 DE 69933891T2
Authority
DE
Germany
Prior art keywords
hpv
vlps
therapeutic vaccine
warts
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69933891T
Other languages
German (de)
English (en)
Other versions
DE69933891D1 (de
Inventor
Jian Zhou
Ctr. For Immunology & Cancer Res. Ian Buranda FRAZER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland
Original Assignee
University of Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland filed Critical University of Queensland
Publication of DE69933891D1 publication Critical patent/DE69933891D1/de
Application granted granted Critical
Publication of DE69933891T2 publication Critical patent/DE69933891T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69933891T 1998-12-11 1999-12-13 Behandlung von papillomavirus-infektionen Expired - Lifetime DE69933891T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP765398 1998-12-11
AUPP7653A AUPP765398A0 (en) 1998-12-11 1998-12-11 Treatment of papillomavirus infections
PCT/AU1999/001108 WO2000035478A1 (en) 1998-12-11 1999-12-13 Treatment of papillomavirus infections

Publications (2)

Publication Number Publication Date
DE69933891D1 DE69933891D1 (de) 2006-12-14
DE69933891T2 true DE69933891T2 (de) 2007-06-21

Family

ID=3811858

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69933891T Expired - Lifetime DE69933891T2 (de) 1998-12-11 1999-12-13 Behandlung von papillomavirus-infektionen

Country Status (12)

Country Link
US (2) US6867033B1 (cg-RX-API-DMAC7.html)
EP (1) EP1144005B1 (cg-RX-API-DMAC7.html)
JP (2) JP5274737B2 (cg-RX-API-DMAC7.html)
KR (1) KR100617485B1 (cg-RX-API-DMAC7.html)
AT (1) ATE344053T1 (cg-RX-API-DMAC7.html)
AU (1) AUPP765398A0 (cg-RX-API-DMAC7.html)
CA (1) CA2353866C (cg-RX-API-DMAC7.html)
DE (1) DE69933891T2 (cg-RX-API-DMAC7.html)
DK (1) DK1144005T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ512850A (cg-RX-API-DMAC7.html)
WO (1) WO2000035478A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA997638B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2284287T3 (es) * 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
FR2802426B1 (fr) * 1999-12-15 2004-04-02 Neovacs Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, pour la production d'iga secretoires
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
EP1422526A1 (en) * 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
WO2006113209A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
US10513541B2 (en) 2015-12-04 2019-12-24 Xiamen University Mutant of L1 protein of human papillomavirus type 11
WO2019081750A1 (en) * 2017-10-27 2019-05-02 Statens Serum Institut VACCINE AGAINST POLYGENIC INFLUENZA
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1359156B1 (en) 1991-07-19 2007-03-07 University of Queensland Vaccine against Human Papillomavirus (Type 18)
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
ES2264126T3 (es) * 1994-05-16 2006-12-16 MERCK & CO., INC. Vacunas contra el papilomavirus.
DE69531256T2 (de) * 1994-09-06 2004-05-27 Scan-Web I/S Verfahren und system zur herstellung von breiten, luftgelegten papierbahnen enthaltend ein absorbierendes pulver
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
AU4258297A (en) 1996-09-11 1998-04-02 Merck & Co., Inc. Papillomavirus vaccine formulation
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ES2273376T3 (es) 1996-12-20 2007-05-01 MERCK & CO., INC. Formulaciones de vacunas recombinantes frente a papilomas.
WO1998044944A2 (en) * 1997-04-08 1998-10-15 Merck & Co., Inc. Stabilized human papillomavirus formulations
DE19735118C1 (de) 1997-08-13 1998-08-13 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties

Also Published As

Publication number Publication date
NZ512850A (en) 2004-01-30
KR20010103711A (ko) 2001-11-23
JP2002532434A (ja) 2002-10-02
JP2011037902A (ja) 2011-02-24
ATE344053T1 (de) 2006-11-15
DK1144005T3 (da) 2007-03-05
US7172870B2 (en) 2007-02-06
WO2000035478A1 (en) 2000-06-22
CA2353866C (en) 2013-11-19
JP5274737B2 (ja) 2013-08-28
US20050244433A1 (en) 2005-11-03
ZA997638B (en) 2000-07-06
CA2353866A1 (en) 2000-06-22
DE69933891D1 (de) 2006-12-14
US6867033B1 (en) 2005-03-15
EP1144005A4 (en) 2005-02-09
EP1144005A1 (en) 2001-10-17
KR100617485B1 (ko) 2006-09-01
AUPP765398A0 (en) 1999-01-14
EP1144005B1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
DE69333859T2 (de) Sich selbst-zusammenbauende rekombinante hpv16 papillomavirus hüllproteine
DE69434383T2 (de) Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
DE69532532T2 (de) Chimerische papillomavirus-ahnliche partikel
DE69233687T2 (de) Impfstoff gegen Humanes Papillomavirus (Typ 18)
Alvarez et al. A pilot study of pNGVL4a-CRT/E7 (detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3)
Zhang et al. HPV6b virus like particles are potent immunogens without adjuvant in man
DE69835294T2 (de) Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virusähnlichen teilchen (vlps)
DE60124918T2 (de) Kodon-optimierte papillomavirussequenzen
DE69836753T2 (de) Papilloma virus capsomere impfstoff-formulierungen und deren verwendungen
EP1728800A1 (de) Papillomavirusähnliche Partikel, Fusionsproteine sowie Verfahren zu deren Herstellung
JP2011037902A (ja) パピローマウイルス感染の治療方法
DE69736779T2 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
DE4435907C2 (de) Papillomavirusähnliche Partikel und deren Anwendung
JP4854742B2 (ja) 抗hpv感染症薬の調製におけるノカルディア・ルブラ細胞壁骨格の使用
KR101359943B1 (ko) Hpv 16과 hpv 18 및 적어도 hpv 31, 45 또는 52로부터 선택된 또 다른 hpv 유형에 대한 백신
KR20080005585A (ko) 백신
KR20070029254A (ko) Hpv 16과 hpv 18 및 적어도 hpv 31, 45 또는52로부터 선택된 또 다른 hpv 유형에 대한 백신
EP1064014B1 (de) Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor
AU762114B2 (en) Treatment of papillomavirus infections
WO1999010744A1 (de) Diagnosekit für hauttest und verfahren zur durchführung desselben
EP1183367B1 (de) Zytotoxisches t-zellepitop des papillomavirus l1-proteins und seine verwendung in diagnostik und therapie
DE19526752C2 (de) Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln
EP1066321A2 (de) Formulierung mit papillomavirus-spezifischem protein, seine herstellung und verwendung
US9308237B2 (en) Papillomavirus virus-like particle or capsomere formulation and its use as microbicide
BRPI0610032A2 (pt) uso de uma proteìna l1 do papilomavìrus humano ou fragmento imunogêico da mesma de um primeiro tipo de hpv, programa de vacinação para proteção contra a infecção e/ou doença por hiv, método para prevenção da infecção e/ou doença por hpv, composição de vacina, e, kit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition